CNR1 and Insulin resistance: It is worth mentioning that the metabolic effects of rimonabant (as the ‘first-in-class’ CB1R blocker) on hepatic lipid metabolism and insulin resistance have been vastly studies and described earlier by multiple groups, including us [76,77,83,[94], [95], [96], [97], [98], [99], [100], [101], [102], [103], [104], [105]].